Please login to the form below

Not currently logged in
Email:
Password:

AMNOG – One Year On...

A review of the impact of new pricing and reimbursement arrangements in Germany

Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.


The expert panel includes

  • Justus Dehnen, Pricing and Market Access Leader, Germany
  • Olaf Zweig, Principal, Global Health Practice, Berlin

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consult

Consult is a bespoke data collection service designed to support marketing research clients in meeting those changing, increasingly focused research...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....